nasdaq:ttoo
|
520960
|
Mar 23rd, 2024 12:00AM
|
T2 Biosystems
|
10K
|
146.00
|
Open
|
|
Mar 23rd, 2024 12:48AM
|
Mar 23rd, 2024 07:30PM
|
T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.
At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. We invite you to apply for one of our open positions at www.t2biosystems.com/careers.
|
Open
|
Sepsis, Hemostasis, Infectious Diseases, Candidemia, and In-vitro diagnostics
|
Open
|
101 Hartwell Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
T2 Biosystems
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ttoo
|
520960
|
Mar 22nd, 2024 12:00AM
|
T2 Biosystems
|
10K
|
146.00
|
Open
|
|
Mar 22nd, 2024 12:20AM
|
Mar 22nd, 2024 07:19PM
|
T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.
At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. We invite you to apply for one of our open positions at www.t2biosystems.com/careers.
|
Open
|
Sepsis, Hemostasis, Infectious Diseases, Candidemia, and In-vitro diagnostics
|
Open
|
101 Hartwell Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
T2 Biosystems
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ttoo
|
520960
|
Mar 21st, 2024 12:00AM
|
T2 Biosystems
|
10K
|
146.00
|
Open
|
|
Mar 21st, 2024 06:03PM
|
Mar 21st, 2024 06:03PM
|
T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.
At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. We invite you to apply for one of our open positions at www.t2biosystems.com/careers.
|
Open
|
Sepsis, Hemostasis, Infectious Diseases, Candidemia, and In-vitro diagnostics
|
Open
|
101 Hartwell Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
T2 Biosystems
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ttoo
|
520960
|
Mar 20th, 2024 12:00AM
|
T2 Biosystems
|
10K
|
146.00
|
Open
|
|
Mar 20th, 2024 02:04AM
|
Mar 20th, 2024 08:04PM
|
T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.
At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. We invite you to apply for one of our open positions at www.t2biosystems.com/careers.
|
Open
|
Sepsis, Hemostasis, Infectious Diseases, Candidemia, and In-vitro diagnostics
|
Open
|
101 Hartwell Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
T2 Biosystems
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ttoo
|
520960
|
Mar 19th, 2024 12:00AM
|
T2 Biosystems
|
10K
|
146.00
|
Open
|
|
Mar 19th, 2024 12:01AM
|
Mar 19th, 2024 06:36PM
|
T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.
At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. We invite you to apply for one of our open positions at www.t2biosystems.com/careers.
|
Open
|
Sepsis, Hemostasis, Infectious Diseases, Candidemia, and In-vitro diagnostics
|
Open
|
101 Hartwell Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
T2 Biosystems
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ttoo
|
520960
|
Mar 18th, 2024 12:00AM
|
T2 Biosystems
|
10K
|
146.00
|
Open
|
|
Mar 18th, 2024 12:46AM
|
Mar 18th, 2024 07:48PM
|
T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.
At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. We invite you to apply for one of our open positions at www.t2biosystems.com/careers.
|
Open
|
Sepsis, Hemostasis, Infectious Diseases, Candidemia, and In-vitro diagnostics
|
Open
|
101 Hartwell Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
T2 Biosystems
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ttoo
|
520960
|
Mar 16th, 2024 12:00AM
|
T2 Biosystems
|
10K
|
146.00
|
Open
|
|
Mar 15th, 2024 11:52PM
|
Mar 16th, 2024 07:35PM
|
T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.
At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. We invite you to apply for one of our open positions at www.t2biosystems.com/careers.
|
Open
|
Sepsis, Hemostasis, Infectious Diseases, Candidemia, and In-vitro diagnostics
|
Open
|
101 Hartwell Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
T2 Biosystems
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ttoo
|
520960
|
Mar 15th, 2024 12:00AM
|
T2 Biosystems
|
10K
|
147.00
|
Open
|
|
Mar 15th, 2024 07:31AM
|
Mar 15th, 2024 09:26AM
|
T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.
At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. We invite you to apply for one of our open positions at www.t2biosystems.com/careers.
|
Open
|
Sepsis, Hemostasis, Infectious Diseases, Candidemia, and In-vitro diagnostics
|
Open
|
101 Hartwell Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
T2 Biosystems
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ttoo
|
520960
|
Mar 14th, 2024 12:00AM
|
T2 Biosystems
|
10K
|
147.00
|
Open
|
|
Mar 13th, 2024 11:51PM
|
Mar 14th, 2024 12:48PM
|
T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.
At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. We invite you to apply for one of our open positions at www.t2biosystems.com/careers.
|
Open
|
Sepsis, Hemostasis, Infectious Diseases, Candidemia, and In-vitro diagnostics
|
Open
|
101 Hartwell Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
T2 Biosystems
|
Health Care
|
Health Care Equipment & Services
|
nasdaq:ttoo
|
520960
|
Mar 13th, 2024 12:00AM
|
T2 Biosystems
|
10K
|
148.00
|
Open
|
|
Mar 12th, 2024 11:45PM
|
Mar 13th, 2024 11:18AM
|
T2 Biosystems is developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Our initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.
At T2 Biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. We invite you to apply for one of our open positions at www.t2biosystems.com/careers.
|
Open
|
Sepsis, Hemostasis, Infectious Diseases, Candidemia, and In-vitro diagnostics
|
Open
|
101 Hartwell Avenue
|
Lexington
|
MA
|
US
|
02421
|
|
T2 Biosystems
|
Health Care
|
Health Care Equipment & Services
|